Single Measurements of Carboxy-Terminal Fibroblast Growth Factor 23 and Clinical Risk Prediction of Adverse Outcomes in CKD.

ABSTRACT:

Rationale & objective

An elevated fibroblast growth factor 23 (FGF-23) level is independently associated with adverse outcomes in populations with chronic kidney disease, but it is unknown whether FGF-23 testing can improve clinical risk prediction in individuals.

Study design

Prospective cohort study.

Setting & participants

Participants in the Chronic Renal Insufficiency Cohort (CRIC) Study (n = 3,789).

Exposure

Baseline carboxy-terminal FGF-23 (cFGF-23) level.

Outcomes

All-cause and cardiovascular (CV) mortality, incident end-stage renal disease (ESRD), heart failure (HF) admission, and atherosclerotic events at 3, 5, and 8 years.

Analytical approach

We assessed changes in model performance by change in area under the receiver operating characte

SUBMITTER: Edmonston D 

PROVIDER: S-EPMC6875624 | biostudies-literature | 2019 Dec

REPOSITORIES: biostudies-literature